Home>>Signaling Pathways>> Neuroscience>> Neurokinin Receptor>>Tradipitant (VLY-686)

Tradipitant (VLY-686) (Synonyms: VLY-686; LY686017)

Catalog No.GC33735

Tradipitant (VLY-686) (VLY-686) is a neurokinin-1 (NK-1) antagonist.

Products are for research use only. Not for human use. We do not sell to patients.

Tradipitant (VLY-686) Chemical Structure

Cas No.: 622370-35-8

Size Price Stock Qty
10mM (in 1mL DMSO)
$175.00
In stock
5mg
$135.00
In stock
10mg
$225.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Tradipitant is a neurokinin-1 (NK-1) antagonist.

Results reveal that Tradipitant ([3H]-LY686017) bind to sections of guinea pig brain with a distribution similar to that previously reported for NK-1 receptors. Areas with the highest density are the accessory olfactory nucleus, anteroventral thalamic nucleus, paraventricular hypothalamic nucleus central amygdaloid nucleus (lateral) and the medial amygdaloid nucleus (anterodorsal)[1].

Autoradiography experiments reveal that intravenously administered Tradipitant ([3H]-LY686017) localizes in the guinea pig brain and has a distribution similar to that described for the NK-1 receptor using agonist or antagonist radioligands[1].

[1]. Gackenheimer SL, et al. In vitro and ex vivo autoradiography of the NK-1 antagonist [³H]-LY686017 in Guinea pig brain. Neuropeptides. 2011 Apr;45(2):157-64.

Reviews

Review for Tradipitant (VLY-686)

Average Rating: 5 ★★★★★ (Based on Reviews and 7 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Tradipitant (VLY-686)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.